Skip to main content
SpringerLink
Log in

Retrospective study of factors associated with progression and remission/regression of diabetic kidney disease-hypomagnesemia was associated with progression and elevated serum alanine aminotransferase levels were associated with remission or regression-

  • Original Article
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

Aim

This study was aimed at retrospectively investigating some common clinical factors, including the serum level of magnesium (Mg), associated with progression and remission/regression of diabetic kidney disease (DKD).

Methods

The subjects were 690 Japanese patients with type 2 diabetes mellitus who were receiving treatment with oral antidiabetic drugs other than SGLT2 inhibitors. Routine clinical data were collected on the first and last day of the observation period. The prognosis of DKD is categorized into four stages according to the Kidney Disease Improving Global Outcomes classification. Progression was defined as transition from any of the lower three risk categories (LR, MIR, HR) at the start of the observation period, to the VHR stage/category at the end of the observation period. Remission/regression was defined as improvement of the risk category by at least one stage from the start to the end of the observation period. Factors associated with progression and regression/remission were investigated using Cox proportional hazards analysis. Furthermore, the factors associated with the annual decrease in eGFR of 5 ml/min/1.73 m2 or more were examined by logistic regression analysis. Factors associated with transition of urinary protein negative to trace or positive, or transition of negative or trace to positive, were investigated by Cox proportional hazard analysis.

Results

The observation period was 2251 ± 1614 days. Age (Exp [B] = 1.10, 95% CI; 1.06–1.14; P < 0.01; 1 year old), serum Mg (Exp [B] = 0.82, 95% CI; 0.71–0.95; P < 0.01); 0.1 mg/dl), and serum HbA1c (Exp [B] = 1.03, 95% CI; 1.01–1.05; P < 0.01: 0.1%) were associated with progression of DKD; on the other hand, serum ALT was associated with the likelihood of remission/regression of DKD (Exp [B] = 1.01, 95% CI; 1.002–1.018; P < 0.05; 1 IU/L). The decline in eGFR was associated with higher HbA1c levels, hypomagnesemia, and lower ALT. The new appearance of trace or overt proteinuria was correlated with higher HbA1c levels, advancing age, hypomagnesemia and hypertriglycemia.

Conclusion

Our findings confirmed previous reports that advancing age and serum HbA1c levels were associated with an increased risk of progression of DKD. Lower serum Mg concentrations were also found to be associated with a high risk of progression of DKD, and interventional studies are needed to confirm a causal relationship. Elevated HbA1c levels and hypomagnesemia were common factors in the decline in eGFR and the appearance of trace or overt proteinuria. Lower serum ALT levels were associated with the decline in eGFR. Since serum ALT is known to decrease as the renal function deteriorates, serum ALT is considered to be a marker of renal function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goto A, Noda M, Inoue M, Goto M, Charvat H. Increasing number of people with diabetes in Japan: is this trend real? Intern Med. 2016;55:1827–30.

    Article  Google Scholar 

  2. Sagoo MK, Gnudi L. Diabetic nephropathy: an overview. Methods Mol Biol. 2020;2067:3–7.

    Article  CAS  Google Scholar 

  3. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032–45.

    Article  CAS  Google Scholar 

  4. Berhane AM, Weil EJ, Knowler WC, Nelson RG, Hanson RL. Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death. Clin J Am Soc Nephrol. 2011;6:2444–51.

    Article  Google Scholar 

  5. Ohkuma T, Jun M, Chalmers J, Cooper ME, Hamet P, Harrap S, et al. Combination of changes in estimated GFR and albuminuria and the risk of major clinical outcomes. Clin J Am Soc Nephrol. 2019;14:862–72.

    Article  CAS  Google Scholar 

  6. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease Chapter 1: Definition and classification of CKD. Kidney Int. 2013;3:5–62.

    Article  Google Scholar 

  7. Radcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums G, Ekinci EI. Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig. 2017;8:6–18.

    Article  CAS  Google Scholar 

  8. Oliveira B, Cunningham J, Walsh SB. Magnesium balance in chronic and end-stage kidney disease. Adv Chronic Kidney Dis. 2018;25:291–5.

    Article  Google Scholar 

  9. Tin A, Grams ME, Maruthur NM, Astor BC, Couper D, Mosley TH, et al. Results from the atherosclerosis risk in communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney Int. 2015;87:820–7.

    Article  CAS  Google Scholar 

  10. Pham PC, Pham PM, Pham PA, Pham SV, Pham HV, Miller JM, et al. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol. 2005;63:429–36.

    Article  CAS  Google Scholar 

  11. Sakaguchi Y, Shoji T, Hayashi T, Suzuki A, Shimizu M, Mitsumoto K, et al. Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease. Diabetes Care. 2012;35:1591–7.

    Article  CAS  Google Scholar 

  12. Hovind P, Tarnow L, Parving HH. Remission and regression of diabetic nephropathy. Curr Hypertens Rep. 2004;6:377–82.

    Article  Google Scholar 

  13. Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant. 2004;19:2784–8.

    Article  Google Scholar 

  14. Jiang G, Luk AOY, Tam CHT, Xie F, Carstensen B, Lau ESH, et al. Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes. Kidney Int. 2019;95:178–87.

    Article  Google Scholar 

  15. Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845–54.

    Article  CAS  Google Scholar 

  16. American Diabetes Association 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(1):S14–31.

    Article  Google Scholar 

  17. Miyazaki H, Babazono A, Nishi T, Maeda T, Imatoh T, Ichiba M, et al. Does antihypertensive treatment with renin-angiotensin system inhibitors prevent the development of diabetic kidney disease? BMC Pharmacol Toxicol. 2015;16:22.

    Article  Google Scholar 

  18. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.

    Article  CAS  Google Scholar 

  19. Krolewski AS, Skupien J, Rossing P, Warram JH. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int. 2017;91:1300–11.

    Article  Google Scholar 

  20. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs. placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321:69–79.

    Article  CAS  Google Scholar 

  21. Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23:19–28.

    Article  Google Scholar 

  22. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.

    Article  CAS  Google Scholar 

  23. Ferrè S, Li X, Adams-Huet B, Maalouf NM, Sakhaee K, Toto RD, et al. Low serum magnesium is associated with faster decline in kidney function: the Dallas Heart Study experience. J Investig Med. 2019;67:987–94.

    Article  Google Scholar 

  24. Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, Mozaffarian D. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2013;98:160–73.

    Article  Google Scholar 

  25. Rebholz CM, Tin A, Liu Y, Kuczmarski MF, Evans MK, Zonderman AB, Crews DC. Dietary magnesium and kidney function decline: the healthy aging in neighborhoods of diversity across the life span study. Am J Nephrol. 2016;44:381–7.

    Article  CAS  Google Scholar 

  26. Gröber U, Schmidt J, Kisters K. Magnesium in prevention and therapy. Nutrients. 2015;7:8199–226.

    Article  Google Scholar 

  27. Hata A, Doi Y, Ninomiya T, Mukai N, Hirakawa Y, Hata J, et al. Magnesium intake decreases Type 2 diabetes risk through the improvement of insulin resistance and inflammation: the Hisayama Study. Diabet Med. 2013;30:1487–94.

    Article  CAS  Google Scholar 

  28. Qu X. Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PLoS ONE. 2013;8:e57720.

    Article  CAS  Google Scholar 

  29. Dong JF, Cruz MA, Aboulfatova K, Martin C, Choi H, Bergeron AL, et al. Magnesium maintains endothelial integrity, upregulates proteolysis of ultra-large von Willebrand factor, and reduces platelet aggregation under flow conditions. Thromb Haemost. 2008;99:586–93.

    Article  CAS  Google Scholar 

  30. Vervloet M. Modifying phosphate toxicity in chronic kidney disease. Toxins (Basel). 2019;11:522.

    Article  CAS  Google Scholar 

  31. Sakaguchi Y, Hamano T, Obi Y, Monden C, Oka T, Yamaguchi S, et al. A randomized trial of magnesium oxide and oral carbon adsorbent for coronary artery calcification in predialysis CKD. J Am Soc Nephrol. 2019;30:1073–85.

    Article  CAS  Google Scholar 

  32. Miyake T, Kumagi T, Hirooka M, Koizumi M, Furukawa S, Ueda T, et al. Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study. J Gastroenterol. 2012;47:696–703.

    Article  CAS  Google Scholar 

  33. Jia G, Di F, Wang Q, Shao J, Gao L, Wang L, et al. Non-alcoholic fatty liver disease is a risk factor for the development of diabetic nephropathy in patients with type 2 diabetes mellitus. PLoS ONE. 2015;10:e0142808.

    Article  Google Scholar 

  34. Orlić L, Mikolasevic I, Bagic Z, Racki S, Stimac D, Milic S. Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link? Gastroenterol Res Pract. 2014;4:847539.

    Google Scholar 

  35. Adiga US, Malawadi BN. Association of diabetic nephropathy and liver disorders. J Clin Diagn Res. 2016;10:BC05–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Ray L, Nanda SK, Chatterjee A, Sarangi R, Ganguly S. A comparative study of serum aminotransferases in chronic kidney disease with and without end-stage renal disease: Need for new reference ranges. Int J Appl Basic Med Res. 2015;5:31–5.

    Article  CAS  Google Scholar 

  37. Candinas D, Keusch G, Schlumpf R, Burger HR, Gmür J, Largiadèr F. Hemolytic-uremic syndrome following kidney transplantation: prognostic factors. Schweiz Med Wochenschr. 1994;124:1789–99.

    CAS  PubMed  Google Scholar 

  38. Ruhl CE, Everhart JE. The association of low serum alanine aminotransferase activity with mortality in the US population. Am J Epidemiol. 2013;178:1702–11.

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Medicine, Nerima General Hospital, 1-24-1 Asahigaoka, Nerima-ku, Tokyo, 176-8530, Japan

    Tatsuo Yanagawa & Koichiro Azuma

  2. Institute of Healthcare Quality Improvement, Public Interest Incorporated Foundation Tokyo Healthcare Foundation, Tokyo, Japan

    Tatsuo Yanagawa & Keiko Koyano

Authors
  1. Tatsuo Yanagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keiko Koyano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koichiro Azuma
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TY designed the study, analyzed, and interpreted the data, performed the literature search, and wrote the first draft of the manuscript. KK collected and. Interpreted the data. KA analyzed and interpreted the data.

Corresponding author

Correspondence to Tatsuo Yanagawa.

Ethics declarations

Conflict of interest

Not applicable.

Author agreement

All authors have read and approved the final version of the manuscript being submitted. They certify that the contents of the article represent the authors’ original work, and that the article had neither been published previously, nor is under consideration for publication in any other journal.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 64 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yanagawa, T., Koyano, K. & Azuma, K. Retrospective study of factors associated with progression and remission/regression of diabetic kidney disease-hypomagnesemia was associated with progression and elevated serum alanine aminotransferase levels were associated with remission or regression-. Diabetol Int 12, 268–276 (2021). https://doi.org/10.1007/s13340-020-00483-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-020-00483-1

Keywords

Search

Navigation